1. Алиева С.Б., Алымов Ю.В., Кропотов М.А. и др. Рак губы. Онкология. Клинические рекомендации. Под ред. М.И. Давыдова. М.: Издательская группа РОНЦ, 2015. С. 17 - 20
2. Пачес А.И. Опухоли головы и шеи. 5-е изд., доп. и перераб. М.: Практическая медицина, 2013. С. 105 - 12
3. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой Состояние онкологической помощи населению России в 2021 году. - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2022. - илл. - 239 с
4. Shah J.P., Patel S. G., Singh B. Head and neck surgery and oncology. 4thedn. P. 204
5. NCCN Clinical Practice Guidelines in Oncology (NCCN ). Cancer of the Lip. Version 1.2022
6. Richards, D. (2015). Adjunctive tests cannot replace scalpel biopsy for oral cancer diagnosis. Evidence-Based Dentistry, 16(2), 46 - 47
7. Babu N.H., Devi B.V.L., Kadiyala S. et al. Accuracy of preoperative ultrasonography in measuring tumor thickness and predicting the incidence of cervical lymph node metastasis in oral cancer. J Dr NTR Univers Health Sci 2018; 7(4):241-4
8. Wouter L. Lodder, Hendrik J. Teertstra, Ing B. Tan et al. Tumour thickness in oral cancer using an intra-oral ultrasound probe. Eur Radiol 2011; 21(1):98-106
9. Fleming A.J., Smith S.P., Paul C.M. et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117(7):1173-9
10. Ellis M.A., Graboyes E.M., Wahlquist A.E., et al. Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. Otolaryngology- Head and Neck Surgery 2018, Vol. 158(4) 649 - 659
11. McCombe D., MacGill K., Ainslie J. et al. Squamous cell carcinoma of the lip: a retrospective review of the Peter MacCallum Cancer Institute experience 1979-88. Aust N Z J Surg 2000; 70(5):358-61
12. De Visscher J.G., van den Elsaker K., Grond A.J. et al. Surgical treatment of squamous cell carcinoma of the lower lip: evaluation of long-term results and prognostic factors - a retrospective analysis of 184 patients. J Oral Maxillofac Surg 1998; 56:814-20
13. Bhandari, K., Wang, D., Li, S., Jiang, B., Guo, Y., Koirala, U., & Du, X. (2014). Primary cN0 lip squamous cell carcinoma and elective neck dissection: Systematic review and meta-analysis. Head & Neck, 37(9), 1392 - 1400
14. Mazeron J.J., Ardiet J.M., et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009; 91(2):150-6
15. , de Carpentier J., Hopper C. et al. Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg 2001; 30(6):504-9
16. De Visscher J.G., Botke G., Schakenraad J.A., van der Waal I. A comparison of results after radiotherapy and surgery for stage I squamous cell carcinoma of the lower lip. Head Neck 1999; 21:526-30
17. Chone, C. T., Magalh es, R. S., Etchehebere, E., Camargo, E., Altemani, A., & Crespo, A. N. (2008). Predictive value of sentinel node biopsy in head and neck cancer. Acta Oto-Laryngologica, 128(8), 920 - 924
18. Babington S., Veness M.J., Cakir B. et al. Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision? ANZ J Surg 2003; 73:621-5
19. De Visscher J.G., Grond A.J., Botke G., van der Waal I. Results of radiotherapy for squamous cell carcinoma of the vermilion border of the lower lip. A retrospective analysis of 108 patients. Radiother Oncol 1996; 39:9-14
20. Bernier J., Cooper J.S. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?, Oncologist 2005; 10(3):215-24
21. Bernier J., van Glabbeke M., Domenge C. et al. Results of EORTC phase III trial 22931 comparing, postoperatively, radiotherapy (RT) to concurrent chemo-radiotherapy (RT-CT) with high dose cisplatin in locally advanced head and neck (H & N) carcinomas (SCC). Eur J Cancer 2001
22. Cooper J.S., Zhang Q., Pajak T.F. et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 84(5):1198-205
23. Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27
24. Posner M.R., Hershock D.M., Blajman C.R. et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-15
25. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., Новик А.В., Романов И.С. Практические рекомендации по лечению злокачественных опухолей головы и шеи // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2021 (том 11). С. 71 - 82
26. Hitt R., Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23(34):8636-45
27. Burtness B., Goldwasser M.A., Flood W. et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-54
28. , P., Catimel, G., Planting et al. (1999). Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 10(1), 119 - 122
29. Forastiere A.A., Metch B., Schuller D.E. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245-51
30. Jacobs C., Lyman G., Velez-Garcia E. et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257-63
31. Grau J.J., Caballero M., Verger E. et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009; 129:1294-9
32. Catimel, G., Verweij, J., Mattijssen, V., et al (1994). Docetaxel (): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology, 5(6), 533-537
33. Guardiola E., Peyrade F., Chaigneau L. et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004; 40:2071-6
34. Vermorken J.B., Trigo J., Hitt R. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-7
35. Martinez-Trufero J., Isla D., Adansa J.C. et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010; 102:1687-91
36. Ferris R., Blumenschein G., Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375:1856-67
37. Ye W., Schmitt, N. C. (2019). Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients? Annals of Translational Medicine, 7(S1), S14-S14. doi:10.21037/atm.2019.01.46
38. Сohen, E. E. W., Souli res, D., Le Tourneau, C., et al. (2018). Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet. doi:10.1016/s0140-6736(18) 31999-8
39. Сhow L.Q., Haddad R., Gupta S. et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016; 34(32):3838-45
40. Machiels J.P., Haddad R.I., Fayette J. et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015; 16:583-94
41. Noronha V., Joshi A., Patil V.M. et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 2018; 36-11:1064-72
42. Looser K.G., Shah J.P., Strong E.W. The significance of "positive" margins in surgically resected epidermoid carcinomas. Head Neck Surg 1978; 1(2):107-11
43. Gorsky M., Epstein J.B., Parry J. et al. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 9792):190-5
44. Jensen S.B., Pedersen A.M., Vissink A. et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 2010; 18(8):1061-79
45. Иванова Г.Е., Мельникова Е.В., Шмонин А.А., Вербицкая Е.В., Аронов Д.М., Белкин А.А., Беляев А.Ф., Бодрова Р.А., Бубнова М.Г., Буйлова Т.В., Мальцева М.Н., Мишина И.Е., Нестерин К.В., Никифоров В.В., Прокопенко С.В., Сарана А.М.О., Стаховская Л.В., Суворов А.Ю., Хасанова Д.Р., Цыкунов М.Б. и др. Пилотный проект "Развитие системы медицинской реабилитации в Российской Федерации": Предварительные результаты реализации на первом и втором этапах медицинской реабилитации. Вестник восстановительной медицины. 2017. N 2 (78). С. 10 - 15.
46. Приказ Министерства здравоохранения РФ от 31 июля 2020 г. N 778н "О Порядке организации медицинской реабилитации взрослых" Зарегистрировано в Минюсте РФ 25 сентября 2020 г. Регистрационный N 60039.
47. Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, Buonaccorso L, de van der Schueren MAE, Baldwin C, Chasen M, Ripamonti CI; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer cachexia in adult patients: ESMO Clinical Practice . ESMO Open. 2021 Jun;6(3):100092. doi: 10.1016/j.esmoop.2021.100092. PMID: 34144781; PMCID: PMC8233663.
48. Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clinical Nutrition. 2021.40; p. 2898-2913.
49. Burgos-Mansilla, B.; Galiano-Castillo, N.; Lozano-Lozano, M.; , C.; Lopez-Garzon, M.; Arroyo-Morales, M. Effect of Physical Therapy Modalities on Quality of Life of Head and Neck Cancer Survivors: A Systematic Review with Meta-Analysis. J. Clin. Med. 2021, 10, 4696. https://doi.org/ 10.3390/jcm10204696
50. Kar A, M R A, Bhaumik U, Rao VUS. Psychological issues in head and neck cancer survivors: Need for addressal in rehabilitation. Oral Oncol. 2020 Nov;110:104859. doi: 10.1016/j.oraloncology.2020.104859. Epub 2020 Jun 18. PMID: 32564916
51. Elaldi R, Roussel LM, Gal J, Scheller B, Chamorey E, Schiappa R, Lasne-Cardon A, Louis MY, , Dassonville O, Poissonnet G, Saada E, Benezery K, Babin E, Bozec A. Correlations between long-term quality of life and patient needs and concerns following head and neck cancer treatment and the impact of psychological distress. A multicentric cross-sectional study. Eur Arch Otorhinolaryngol. 2021 Jul;278(7):2437-2445. doi: 10.1007/s00405-020-06326-8. Epub 2020 Sep 8. PMID: 32901366
52. Dias JF, Oliveira VC, Borges PRT, et al Effectiveness of exercises by telerehabilitation on pain, physical function and quality of life in people with physical disabilities: a systematic review of randomised controlled trials with GRADE recommendations British Journal of Sports Medicine 2021; 55:155-162
53. Silver J.A., Baima J. Cancer prehabilitation: anopportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2103; 92(8):715-27
54. Govender R., Smith C.H., Gardner B. Et al. Improving swallowing outcomes in patients with head and neck cancer using a theory-based pretreatment swallowing intervention package: protocol for a randomised feasibility study. BMJ Open 2017; 7(3):e014167
55. Clarke P., Radford K., Coffey M., Stewart M. Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130(S2):176-80
56. Cнеговой А.В., Бесова Н.С., Веселов А.В. и др. Практические рекомендации по нутритивной поддержке у онкологических больных. Злокачественные опухоли 2016; 4(2): 434 - 450
57. Сolevas A.D., Yom S.S., Pfister D.G. et al. NCCN Guidelines Insights: head and neck cancers. Version 1.2018. J Natl Compr Canc Netw 2018; 16(5):479-90
58. Arends J., Bachmann P., Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36(1): 11 - 48
59. Talwar, B., Donnelly, R., Skelly, R., & Donaldson, M. (2016). Nutritional management in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. The Journal of Laryngology & Otology, 130(S2), S32 - S40
60. Linda Denehy, Lara Edbrooke, The Role of Exercise Before Cancer Treatment, Seminars in Oncology Nursing, 2022, 151330, ISSN 0749-2081, https://doi.org/10.1016/j.soncn.2022.151330
61. Takenaka Y, Takemoto N, Oya R, Inohara H. Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: A meta-analysis. PLoS One. 2021 Oct 29; 16(10):e0259288. doi: 10.1371/journal.pone.0259288. PMID: 34714876; PMCID: PMC8555817
62. Hubera G.F., Dort J.C. Reducing morbidity and complications after major head and neck cancer surgery: the (future) role of enhanced recovery after surgery protocols. Curr Opin Otolaryngol Head Neck Surg 2018, 26(2):73-5
63. Coyle, M. J., Main, B., Hughes, C., et al. (2016). Enhanced recovery after surgery (ERAS) for head and neck oncology patients. Clinical Otolaryngology, 41(2), 118 - 126. doi:10.1111/coa.12482
64. Midgley A.W., Lowe D., Levy A.R. et al. Exercise program design considerations for head and neck cancer survivors. Eur Arch Otorhinolaryngol 2018; 275(1):169-79
65. Guru K., Manoor U.K., Supe S.S. A comprehensive review of head and neck cancer rehabilitation: physical therapy perspectives. Indian J Palliat Care. 2012; 1 8(2): 87 - 97
66. Swarm R.A., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2013; 11(8): 992 - 1022
67. Wall L.R., Ward E.C., Cartmill B., Hill A.J. Physiological changes to the swallowing mechanism following (chemo) radiotherapy for head and neck cancer: a systematic review. Dysphagia 2013; 28(4):481-93
68. Govender R., Smith C.H., Taylor S.A. et al. Swallowing interventions for the treatment of dysphagia after head and neck cancer: a systematic review of behavioural strategies used to promote patient adherence to swallowing exercises. BMC Cancer 2017; 17(1):43
69. Starmer, H. M., Ayoub, N., Byward, C., et al. (2017). The impact of developing a speech and swallow rehab program: Improving patient satisfaction and multidisciplinary care. The Laryngoscope, 127(11), 2578 - 2581
70. Harris AS. Do patients benefit from physiotherapy for shoulder dysfunction following neck dissection? A systematic review. J Laryngol Otol. 2020 Jan 22:1-5. doi: 10.1017/S0022215120000079. Epub ahead of print. PMID: 31964434
71. Shareef S, Newton BW. Accessory Nerve Injury. [Updated 2022 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan - https://www.ncbi.nlm.nih.gov/books/NBK532245/
72. Fischlechner R, Kofler B, Schartinger VH, Dudas J, Riechelmann H. Does low-level laser therapy affect the survival of patients with head and neck cancer? Lasers Med Sci. 2021 Apr; 36(3): 599 - 604. doi: 10.1007/s10103-020-03073-4. Epub 2020 Jun 25. PMID: 32583188
73. Mina D.S., Alibhai S.M.H., Matthew A.G. et al. Exercise in clinical cancer care: a call to action and program development description. Curr Oncol 2012; 19(3):136-44
74. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a clinical practice guideline. Curr Oncol 2017; 24(1):40-6
75. Lynch PT, Horani S, Lee R, Sumer BD, Lee SC, Mayo HG, Rethorst C, Day AT. Effectiveness of physical activity interventions in improving objective and patient-reported outcomes in head and neck cancer survivors: A systematic review. Oral Oncol. 2021 Jun; 117:105253. doi: 10.1016/j.oraloncology.2021.105253. Epub 2021 Apr 23. PMID: 33901767
76. Fried J, Etter JL, Stenzel AE, Joseph JM, Cannioto R, Danziger IR, Moysich KB. Physical inactivity and head and neck cancer mortality. Head Neck. 2020 Sep; 42(9):2516-2523. doi: 10.1002/hed.26283. Epub 2020 Jun 1. PMID: 32478442; PMCID: PMC8393317
77. Pauli N., Svensson U., Karlsson T., Finizia C. Exercise intervention for the treatment of trismus in head and neck cancer - a prospective two-year follow-up study. Acta Oncol 2016;55(6):686-92
78. Shao CH, Chiang CC, Huang TW. Exercise therapy for cancer treatment-induced trismus in patients with head and neck cancer: A systematic review and meta-analysis of randomized controlled trials. Radiother Oncol. 2020 Oct; 151: 249 - 255. doi: 10.1016/j.radonc.2020.08.024. Epub 2020 Sep 3. PMID: 32890607
79. Chee S, Byrnes YM, Chorath KT, Rajasekaran K, Deng J. Interventions for Trismus in Head and Neck Cancer Patients: A Systematic Review of Randomized Controlled Trials. Integr Cancer Ther. 2021 Jan-Dec; 20:15347354211006474. doi: 10.1177/15347354211006474. PMID: 34014116; PMCID: PMC8145608
80. Goyal N, Day A, Epstein J, Goodman J, Graboyes E, Jalisi S, Kiess AP, Ku JA, Miller MC, Panwar A, Patel VA, Sacco A, Sandulache V, Williams AM, Deschler D, Farwell DG, Nathan CA, Fakhry C, Agrawal N. Head and neck cancer survivorship consensus statement from the American Head and Neck Society. Laryngoscope Investig Otolaryngol. 2021 Nov 30; 7(1): 70 - 92. doi: 10.1002/lio2.702. PMID: 35155786; PMCID: PMC8823162
81. McLaughlin TM, Broadhurst JJ, Harris CJ, McGarry S, Keesing SL. A randomized pilot study on self-management in head and neck lymphedema. Laryngoscope Investig Otolaryngol. 2020 Sep 15; 5(5): 879 - 889. doi: 10.1002/lio2.455. PMID: 33134535; PMCID: PMC7585235
82. Tyker A, Franco J, Massa ST, Desai SC, Walen SG. Treatment for lymphedema following head and neck cancer therapy: A systematic review. Am J Otolaryngol. 2019 Sep-Oct; 40(5): 761 - 769. doi: 10.1016/j.amjoto.2019.05.024. Epub 2019 May 30. PMID: 31174933
83. Doke K.N., Bowman L., Shnayder Y. et al. Quantitative clinical outcomes of therapy for head and neck lymphedema. Adv Radiat Oncol 2018; 3(3):366-71
84. Tacani P.M., Franceschini J.P., Tacani R.E. et al. Retrospective study of the physical therapy modalities applied in head and neck lymphedema treatment. Head Neck 2016; 38(2):301-8
85. Piso, D. U., Eckardt, A., Liebermann, A., Gutenbrunner, C., , P., & Gehrke, A. (2001). Early Rehabilitation of Head-Neck Edema After Curative Surgery for Orofacial Tumors. American Journal of Physical Medicine & Rehabilitation, 80(4), 261 - 269
86. Lee N., Wigg J., Carroll J.D.The use of low level light therapy in the treatment of head and neck oedema. J Lymphoedema 2013; 8(1): 35 - 42
87. Ткаченко Г.А. Клинико-психологическое исследование качества жизни больных, страдающих злокачественными новообразованиями челюстно-лицевой области. Вестник психотерапии 2012; 44(49): 57 - 63
88. Zhao, S. G., Alexander, N. B., Djuric, Z., Zhou, J., Tao, Y., Schipper, M.,... Jolly, S. (2015). Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head & Neck, 38(S1), E1086-E1096
89. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a systematic review. Curr Oncol. 2017 Aug; 24(4): e290 - e315
90. Samuel S.R., Maiya G.A., Fernandes D.J. et al. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer 2019
91. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3(7):961-8
92. Bye A, Sandmael JA, Stene GB, Thorsen L, Balstad TR, Solheim TS, Pripp AH, Oldervoll LM. Exercise and Nutrition Interventions in Patients with Head and Neck Cancer during Curative Treatment: A Systematic Review and Meta-Analysis. Nutrients. 2020 Oct 22; 12(11):3233. doi: 10.3390/nu12113233. PMID: 33105699; PMCID: PMC7690392
93. Fabi A, Bhargava R, Fatigoni S, Guglielmo M, Horneber M, Roila F, Weis J, Jordan K, Ripamonti CI; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment. Ann Oncol. 2020 Jun; 31(6): 713 - 723. doi: 10.1016/j.annonc.2020.02.016. Epub 2020 Mar 12. PMID: 32173483
94. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain, version 1.2022 - January 19, 2022. Available at https://www.nccn.org/professionals/physician_gls/default.aspx#supportive. Accessed January 25, 2022
95. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020 Oct; 31(10): 1306 - 1319. doi: 10.1016/j.annonc.2020.07.003. Epub 2020 Jul 30. PMID: 32739407
96. Menendez AG, Cobb R, Carvajal AR, et al: Effectiveness of massage therapy as a treatment strategy and preventive modality for chemotherapy-induced peripheral neuropathy symptoms. 2016 Palliative and Supportive Care in Oncology Symposium. Abstract 193.
97. , M., Villar-Taibo, R., , A. et al. Early versus conventional nutritional intervention in head and neck cancer patients before radiotherapy: benefits of a fast-track circuit. Eur J Clin Nutr 75, 748 - 753 (2021)].. https://doi.org/10.1038/s41430-020-00786-1)
98. Сытов А.В., Зузов С.А., Кукош М.Ю., Лейдерман И.Н., Потапов А.Л., Хотеев А.Ж. Практические рекомендации по нутритивной поддержке онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2021 (том 11)
99. Robijns J, Lodewijckx J, Claes S, Van Bever L, Pannekoeke L, Censabella S et al (2021) Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial). Radiother Oncol 158: 268 - 275
100. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1; 126(19): 4423 - 4431. doi: 10.1002/cncr.33100. Epub 2020 Jul 28. Erratum in: Cancer. 2021 Oct 1; 127(19):3700. PMID: 32786044; PMCID: PMC7540329
101. Klausner, G., Troussier, I., Canova, CH. et al. Clinical use of photobiomodulation as a supportive care during radiation therapy. Support Care Cancer 30, 13 - 19 (2022). https://doi.org/10.1007/s00520-021-06518-w
102. Mercadante V, Jensen SB, Smith DK, Bohlke K, Bauman J, Brennan MT, Coppes RP, Jessen N, Malhotra NK, Murphy B, Rosenthal DI, Vissink A, Wu J, Saunders DP, Peterson DE. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline. J Clin Oncol. 2021 Sep 1; 39(25): 2825 - 2843. doi: 10.1200/JCO.21.01208. Epub 2021 Jul 20. PMID: 34283635
103. Ni X, Tian T, Chen D, Liu L, Li X, Li F, Liang F, Zhao L. Acupuncture for Radiation-Induced Xerostomia in Cancer Patients: A Systematic Review and Meta-Analysis. Integr Cancer Ther. 2020 Jan - Dec; 19:1534735420980825. doi: 10.1177/1534735420980825. PMID: 33307864; PMCID: PMC7739209
104. Dymackova R, Selingerova I, Kazda T, Slavik M, Halamkova J, Svajdova M, Slampa P, Slama O. Effect of Acupuncture in Pain Management of Head and Neck Cancer Radiotherapy: Prospective Randomized Unicentric Study. J Clin Med. 2021 Mar 7; 10(5):1111. doi: 10.3390/jcm10051111. PMID: 33799949; PMCID: PMC7961644
105. Ravi P, Vaishnavi D, Gnanam A, Krishnakumar Raja VB. The role of hyperbaric oxygen therapy in the prevention and management of radiation-induced complications of the head and neck - a systematic review of literature. J Stomatol Oral Maxillofac Surg. 2017 Dec; 118(6): 359 - 362. doi: 10.1016/j.jormas.2017.07.005. Epub 2017 Aug 22. PMID: 28838774.
106. Walker M.P., Wichman B., Cheng A.L. et al. Impact of radiotherapy dose on dentition breakdown in head and neck cancer patients. Pract Radiat Oncol 2011; 1(3):142-8
107. Little M., Schipper M., Feng F.Y. et al. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys 2012; 83(3):1007-14
108. Studer G., Glanzmann C., Studer S.P. et al. Risk-adapted dental care prior to intensity-modulated radiotherapy (IMRT). Schweiz Monatsschr Zahnmed 2011; 121(3):216-9
109. Sim, C. P. C., Walker, G. D., Manton, D. J., Soong, Y.-L., Wee, J. T. S., Adams, G. G., & Reynolds, E. C. (2018). Anticariogenic efficacy of a saliva biomimetic in head-and-neck cancer patients undergoing radiotherapy. Australian Dental Jour-nal.doi:10.11
110. Al-Joburi W., Clark C., Fisher R. A comparison of the effectiveness of two systems for the prevention of radiation caries //Clinical preventive dentistry. - 1991. - Т. 13. - N. 5. - С. 15 - 19
111. Lee I.J., Koom W.S., Lee C.G. et al. Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys 2009; 75(4):1084-91
112. Jacobsson H, Radiological detection of bone and bone marrow metastases. Med Oncol Tumor Pharmacother. 1991; 8(4):253-60.
113. , , Petera J. Is There Still a Place for Brachytherapy in the Modern Treatment of Early-Stage Oral Cancer? Cancers (Basel). 2022 Jan 3; 14(1):222.
114. Hall SF, Owen T, Griffiths RJ, Brennan K. Does the frequency of routine follow-up after curative treatment for head-and-neck cancer affect survival? Curr Oncol. 2019 Oct; 26(5): 295 - 306.
115. De Felice F, Lei M, Oakley R, Lyons A, Fry A, Jeannon JP, Simo R, Guerrero Urbano T. Risk stratified follow up for head and neck cancer patients - An evidence based proposal. Oral Oncol. 2021 Aug; 119:105365.
116. Guigay J, Fayette J, Dillies A-F, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03 [abstract]. J Clin Oncol 2012; 30(suppl 15):Abstract 5505.
117. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562 - 3567
118. Lala M, Li M, Sinha V, de Alwis D, Chartash E, Jain L. A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation. J Clin Oncol. 2018; 36 (suppl; abstr 306)
119. Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987; 71: 723 - 726.
120. Specht L, Larsen SK, Hansen HS Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. .Ann Oncol. 2000 Jul; 11(7):845-9.
121. Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., Кутукова С.И., Новик А.В., Романов И.С. Практические рекомендации по лекарственному лечению опухолей головы и шеи. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023 (том 13), #3s2, стр. 100 - 119.
122. Narveson L, Kathol E, Rockey M, Henry D, Grauer D, Neupane P.Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. Med Oncol. 2016 Oct; 33(10):107.
123. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394: 1915 - 1928.
124. Степанова А.М., Гамеева Е.В., Германова О.В., Огнев Ю.Н. Современные технологии реабилитации онкологических больных: обзор международного опыта. Злокачественные опухоли 2022; #3s1: 48 - 56
125. Мельникова Е.В., Буйлова Т.В., Бодрова Р.А., Шмонин А.А., Мальцева М.Н., Иванова Г.Е. Использование международной классификации функционирования (МКФ) в амбулаторной и стационарной медицинской реабилитации: инструкция для специалистов // Вестник Восстановительной медицины, N 6 (82) 2017.
126. Sheibani, K.M.; Mafi, A.R.; Moghaddam, S.; Taslimi, F.; Amiran, A.; Ameri, A. Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: A double-blind placebo-controlled randomized clinical trial. Asia-Pac. J. Clin. Oncol. 2015, 11, 22 - 27.
- Гражданский кодекс (ГК РФ)
- Жилищный кодекс (ЖК РФ)
- Налоговый кодекс (НК РФ)
- Трудовой кодекс (ТК РФ)
- Уголовный кодекс (УК РФ)
- Бюджетный кодекс (БК РФ)
- Арбитражный процессуальный кодекс
- Конституция РФ
- Земельный кодекс (ЗК РФ)
- Лесной кодекс (ЛК РФ)
- Семейный кодекс (СК РФ)
- Уголовно-исполнительный кодекс
- Уголовно-процессуальный кодекс
- Производственный календарь на 2025 год
- МРОТ 2024
- ФЗ «О банкротстве»
- О защите прав потребителей (ЗОЗПП)
- Об исполнительном производстве
- О персональных данных
- О налогах на имущество физических лиц
- О средствах массовой информации
- Производственный календарь на 2024 год
- Федеральный закон "О полиции" N 3-ФЗ
- Расходы организации ПБУ 10/99
- Минимальный размер оплаты труда (МРОТ)
- Календарь бухгалтера на 2024 год
- Частичная мобилизация: обзор новостей